The goal of this project is to develop biologics that direct release of target protein extracellular domains from the membrane. As this strategy is general, it has the potential for broad impact as a method to shed a pathologic protein ectodomain and silence its activity. The long-term development plan is to extend this technology to silence the functions of a broad range of target proteins.
Funding
Funding Duration
January 12, 2026 - January 11, 2027
Funding level
Emergency
People
Principal Investigator
Stephen Blacklow
MD, PhD
Gustavus Adolphus Pfeiffer Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
Collaborators
Rhiannon Moss
PhD